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The nuclear magnetic resonance (NMR) method
makes it possible to analyse the chemical
constituents of living animals or humans repeatedly
and non-invasively. It has mainly been applied to
the study of endogenous phosphorylated or carbon
containing compounds (Gadian, 1982; Iles et al.,
1982) but could equally be used to trace the
metabolic fate of exogenously administered
substances such as drugs. At present it is necessary
to kill many animals in order to determine the fate
of a drug at its target site (or at the sites where it is
detoxified) and it is almost impossible to obtain
such information in humans. By using new in vivo
NMR techniques it should be possible to follow the
metabolic fate of a drug either in an animal or
patient. The most favourable atomic nucleus for
studies of this kind is 19F: there is no background
from endogenous compounds, 19F gives intense
NMR signals with a wide chemical shift range, and
many fluorinated drugs are in clinical use. In this
paper we describe the use of '9F NMR to monitor
the metabolism of 5-fluorouracil in tumours and in
the liver.
The fluorinated pyrimidines, 5-fluorouracil (5FU),
5-fluorouridine (FUrd) and 5-fluoro-2-deoxyuridine
(FdU) are widely used in the treatment of
disseminated human cancers, especially of the
gastrointestinal tract, breast and ovary (Martindale,
1982). The metabolism of these drugs has been
extensively studied and it is clear that with a few
important exceptions they participate in the same
pathways as uracil and its metabolites (Figure 1).
Treatment with fluorinated pyrimidines produces
two major effects in cells: (i) inhibition of DNA
synthesis by inhibition of dTMP synthetase (EC
2.1.1.41) by fluorodeoxyuridine monophosphate
(FdUMP) (Heidelberger, 1974); and (ii) alteration in
the processing and function of some types of RNA
because of extensive incorporation of 5FU in place
of uracil (Heidelberger, 1974; Carrico & Glazer,
1979). Which of these effects accounts for the major
antitumour property of these drugs is a matter of
contention.
Recent studies have been directed at developing
combined chemotherapeutic regimens which
incorporate the fluorinated pyrimidines with drugs
such as methotrexate, thymidine or PALA (Goulian
et al., 1980; Bedikian et al., 1981; Au et al., 1982) or.
developing new analogues (Sakurai, 1981). In both
cases the aim is to alter the rate and fate of
metabolism of the drug and hence increase its
therapeutic efficacy.
Major problems in this area are the provision of
precise methods with the ability to quantify all
aspects of metabolism of the drug: its metabolites
are unstable and difficult to detect. Pogolotti et al.
(1981) and Sommadossi et al. (1982) have overcome
many of these problems, but conventional analysis
of uptake into solid tumour models has a number
of difficulties, not least in satisfactory removal of
the tissue. Studies on 5FU metabolism in cell
culture cannot give information about the uptake
or fate of the drug in an intact tumour (Pogolotti et
al., 1981), while plasma pharmacodynamics give at
best only a very indirect assessment of a drug's
efficacy (Cano et al., 1981).
We were able to follow the metabolism of i.v.
injected 5FU in situ both in implanted tumours and
livers of C57 mice by `9F-NMR using surface coils.
Livers were examined in either female C57 or
C57BI/Cbi mice. Lewis lung carcinomas were
implanted in female C57BI/Cbi mice by s.c.
injection of 2.5 x 104 viable tumour cells (obtained
by trypsin/DNase digestion) over the sacral region
and studied at a mean diameter of 6-7mm. Animals
were anaesthetised using sodium pentobarbitone
60mgkg-1 by i.p. injection. A 25mgml-1 solution
of 5FU (Roche Products) was then injected into the
jugular vein. For NMR spectroscopy mice were
secured vertically within a purpose built probe. By
means of an abdominal incision a flat one turn
7mm diameter radiofrequency (R.f.) coil was placed
on the surface of the liver. To prevent evaporation
and to electrically insulate the coil, the liver surface
was covered with a thin plastic film. In the case of
tumour-bearing mice the coil was laid over the
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Figure 1 The pathway of 5FU metabolism. 5FU (5-fluorouracil), FUR (fluorouracil ribose) FUMP, FUDP,
FUTP (fluorouracil mono, di and triphosphate); FUdR (fluorouracil deoxyribose); FdUMP, FdUDP, FdUTP
(fluorodeoxyuracil mono, di, triphosphate); FUH2 (dihydrofluorouracil); FUPA (fluoro-f,-ureidopropionic
acid); Fflala (fluoro-fl-alanine).
tumour. The probe was inserted into the magnet of
a wide bore Bruker WM200 spectrometer. 19F
spectra were recorded at an irradiation frequency of
188MHz and a sweep width of +6000Hz with 4K
data points. Radiofrequency pulses of 5jus pulse
width with a recycle time of 0.5 s were used. For all
spectra the line broadening was 12Hz. Integration
of NMR peaks was by the method of cut and weigh
(Iles et al., 1982). Each experiment was performed
on three occasions with essentially identical results.
The figures show the result of a typical experiment
in each case.
The results (Figure 2) clarify a number of steps in
the pathway of 5FU metabolism (Figure 1).
Degradation of 5FU proceeds by reduction of the
pyrimidine ring and then hydrolysis to fluoro-/3-
ureidopropionic acid (FUPA) which is subsequently
hydrolysed to fluoro-,B-alanine (F/ala), NH+ and
CO2. From the spectra in Figure 2a it is clear that
a small dose of 5FU is fully converted to
dihydrofluorouracil (FUH2) and F,Bala within
30min. Most of the FUH2 is then converted to
Fflala within a further 3 h. After higher doses of
5FU (180mgkg-t) a constant FUH2 peak was seen
throughout the experiment (Figure 2b), although a
fall in 5FU and a rise in the Fflala peak was taking
place. No conversion of 5FU to toxic nucleosides or
nucleotides was observed in the liver, even at high
dosages.
By contrast, tumour tissue degrades 5FU at a
much slower rate and the catabolic products found
in the liver were not detected. Low or high doses of
5FU were converted to deoxynucleotide and
deoxynucleoside derivatives (Figure 2c and d). For
reasons discussed in the legend to Figure 2 we were
unable to resolve the mono-, di- and tri-phosphate
derivatives so we have assigned this peak as
FdUMP. In a control experiment a '9F signal was
not obtained from muscle in the sacral region.
Pogolotti et al. (1981) found that all the 3H-5FU
taken up by cultured cells was tightly bound to
proteins; 5FdUMP complexed in this manner
would probably be invisible by NMR. In the high
dose experiments (180mgkg-1) there was
considerable conversion of 5FU to 5FdUMP
(Figure 2d). This peak had a narrow linewidth
(126Hz) suggesting that the 5FdUMP was free in
solution. In contrast, at the low dose (30mgkg-1),
the formation of 5FdUMP was barely detectable,
although the linewidth of its peak was consistent
with a compound in a mobile environment. The
weak signal from 5FdUMP suggests that most of
the metabolite was in an environment invisible to
NMR, perhaps bound to a protein.
It has been suggested that thymidine could be
used to protect normal cells against 5FU toxicity
while potentiating its antitumour effect. 5FU is
thought to act by conversion to 5dUMP which
inhibits thymidylate synthetase or by conversion to
5-FUTP which causes incorporation of 5FU into
RNA. Thymidine has been found to enhance 5FU
incorporation into RNA of some tumour cell lines
but not into bone marrow or gut cells (Speigelman
et al., 1980).
The experiments we have carried out in which
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Figure 2 Uptake of 5-fluorouracil (5FU) into liver and implants of Lewis lung tumour in C57 mice
monitored by "9F NMR spectroscopy after the i.v. injection of 30mgkg-1 5FU (a,c) and 180mgkg-1 5FU
(b,d) into the jugular vein. Peak assignments have been obtained from aqueous tissue extracts doped with
tracer amounts of the suspected compounds. Times refer to time after injection of 5FU. Peak A (A) arises
primarily from the conversion of 5FU to the major anabolic product FdUMP and probably contains
contributions from the corresponding di- and tri-phosphates. When prepared from FdUMP by the action of
nucleoside monophosphate kinase (13) both gave resonances shifted only lppm upfield from FdUMP when
dissolved in 100pM TEA buffer pH 7.6.
Peak B (A) corresponds to the peak of 5FdU and is only visible after concurrent thymidine therapy (Figure
3). Peak C (0,O) is 5FU. Peak D (0, LI) probably represents the first ring cleavage product of the 5FU
catabolic pathway (FUH2). Peak E (*, O) corresponds to fluor-f,-alanine (Ffala) the end product of 5FU
metabolism. Chemical shift values have been derived from the assignment of 5FU and Ff3ala which provide
non-titrable internal references. All shift values are given relative to a pure solution of fluorotryptophan.
simultaneously with 5FU (30 mgkg- 1) are
consistent with the suggestion that thymidine
enhances 5FU toxicity by competing with 5FU for
catabolic pathway enzymes in the liver and so
prolongs 5FU clearance (Kirkwood et al., 1980). A
second effect is the appearance of deoxyuracil
derivatives; this is suprising as they are not seen
after administration of high doses of 5FU alone.
Thymidine is known to induce the synthesis of
thymidine phosphorylase which catalyses the
conversion of 5FU to the toxic 5FUdR (Ardalan &
Glazer, 1981). The most probable assignment of
peak B in Figure 3a is 5FUdR.
The titration curve of 5FuDR showed a pK of
7.5; thus FUdR could clearly serve as a probe for
intracellular pH. When injected into control mice at
a dose of 180mgkg-' the 5FUdR gave a peak in
the spectrum from liver with a chemical shift
corresponding to an intracellular pH of 7.2+0.05
(n=5). This compares with measurements of
intracellular pH in a similar group of mice using
the 3'P-NMR signal of Pi of 7.4+0.6, P=0.05
(n= 5).
In order to estimate the sensitivity of the
technique (and to determine the 5FU signal likely
to arise from the extra-cellular space) we repeated
the experiments using 5-fluoro[6-14C]uracil at
30mgkg-'. There was a rapid elimination from the
blood in the first 30min followed by a slower phase
(Figure 4a) whereas the accumulation of
radioactivity in the liver reached a plateau at
60min. A similar curve was observed when the total
fluorine integrals of the liver spectra were measured.
From these data we calculate the the minimum
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Figure 3 The uptake of 5FU into the liver of C57 mice monitored by '9F NMR spectroscopy after injection
of 5FU 30mgkg-1+thymidine 180mgkg- . Peak assignments are given in the legend for Figure 2.
concentration of 5FU observable in the current
series of experiments by '9F NMR was 0.5pmolg- 1
wet wt. The NMR signal from 5FU in the blood
and extracellular space of the liver (and also of the
tumour) will clearly be negligible at this dose
(Figure 4b).
19F NMR can provide a direct, non-invasive
measurement of the metabolism of a fluorinated
drug both at its site of action and at its site(s) of
detoxification. The action of adjuvant drugs on its
metabolism can readily be demonstrated.
NMR observations of tumours in patients are
now possible (Griffiths et al., 1983) so the present
method could be extended to clinical medicine. In
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addition to basic studies on drug metabolism of the
kind described above it should prove possible to
obtain a non-invasive assay of a drug and its
metabolites at its sites of action in each patient and
this would clearly assist patient management.
Although "9F is especially favourable this method
need not be restricted to this nucleus. 13C labelling
for example (Alger et al., 1981) could be used in
almost any drug.
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Figure 4 (a) The uptake of "4C label into mouse liver after the injection of 30mgkg-1 5FU containing
2.2pCi 5-fluoro-[6-'4C]uracil (Amersham International): (b) the elimination of "4C label from the blood
stream. Results are the means of 5 experiments in each case; bars indicate s.e. Livers were removed by freeze
clamping, extracted in 10% TCA and neutralised with Tris base. Blood was taken from the vena cava and
quenched in an equal volume of TCA. Aliquots were counted by liquid scintillation.
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